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Abstract
Background: Chlorhexidine gluconate (CHG) is a broad-spectrum antiseptic agent
that has become widely used for mouth care in intubated patients. Many studies have
found it to be effective in the prevention of ventilator-associated pneumonia (VAP) when
used after intubation; however, there is very limited research exploring the proper time to
initiate CHG. Purpose: The purpose of this systematic review was to determine if the use
of oral care with CHG prior to intubation impacts the incidence of VAP. Methods: The
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) was
used to guide the selection process of articles and the Critical Appraisal Skills
Programme (CASP) was used to critically appraise the randomized control trials (RCTs)
selected for this systematic review. Four randomized RCTs met inclusion criteria.
Results: Three of the four RCTs which met inclusion criteria, Houston et al. (2002),
DeRiso et al. (1996), and Lin et al. (2015), showed an improvement in VAP rates with
the use of preintubation CHG in cardiac surgery patients. Only one RCT, the Munro et al.
(2015) study, showed no benefit; this was the only study that included non-cardiac
surgery patients. Conclusion: Based on the results of this systematic review, it can only
be recommended that cardiac surgery patients receive CHG prior to or after intubation;
however, more research needs to be done to determine the most effective dosing,
frequency, and CHG application procedure. In addition, further study exploring the safety
of administering CHG prior to intubation in noncardiac surgery patients is needed.
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Does Oral Chlorhexidine Mouth Care Prior to Intubation Impact
Ventilator-Associated Pneumonia?
A Systematic Review
Background/Statement of the Problem
Hospital-acquired infections (HAIs) have a significant impact on mortality and
health care costs. The five HAIs identified by the Centers for Disease Control and
Prevention (CDC) include central line-associated bloodstream infections (CLABSI),
catheter-associated urinary tract infection (CAUTI), surgical site infection (SSI),
clostridium difficile-associated diarrhea (CDAD), and ventilator-associated pneumonia
(VAP) (CDC, 2010). According to the National Nosocomial Infection Surveillance
System VAP is the second most common nosocomial infection after urinary tract
infections. Ventilator-associated pneumonia occurs in 9–27% of all intubated patients
(American Thoracic Society; Infectious Diseases Society of America, 2005) leading to
prolonged intubation and hospitalizations. A diagnosis of VAP can have a huge impact
on mortality with an estimated cost upwards of $40,000 per patient and a mortality rate
estimated between 27-76% (Klompas, Speck, Howell, et al., 2014).
The Centers for Medicare and Medicaid Services listed VAP as one of the most
reasonably preventable diseases. Sedwick et al. (2012) explain that since the centers view
VAP as preventable, insurance companies may not reimburse hospitals for the diagnosis
of VAP leading to a huge economic burden. With such a large mortality and financial
burden, many hospitals utilize “VAP Bundles” which provide strategies to prevent the
occurrence of VAP. Components of the VAP bundle may include: elevation of the head
of the bed to 30º to 45º; prophylaxis for peptic ulcer disease; prophylaxis for deep-vein
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thrombosis; daily interruption of sedation (sedation holiday); daily assessment of
readiness for extubation; and daily oral care with chlorhexidine.
Chlorhexidine gluconate (CHG) is a broad-spectrum antiseptic agent that has
become widely used for mouth care in intubated patients. Many studies have found it to
be effective in the prevention of VAP when used after intubation. There is very limited
research exploring the proper time to initiate chlorhexidine. The purpose of this paper
was to determine if the use of oral care with chlorhexidine prior to intubation impacts the
incidence of ventilator-associated pneumonia.
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Literature Review
A literature search was performed using CINHAL, Google Scholar, Cochrane,
and Medscape combining the key terms: ventilator-associated pneumonia; chlorhexidine;
and oral care. The additional term prior to intubation was also included later in the
literature search. Literature was searched from 2005 to 2020. Searches were limited to the
English language and articles that included adults 18 years and older.
The Body’s Natural Defense Mechanisms for Prevention of Respiratory Infection
A healthy person has multiple host defense mechanisms that hinder the
development of pneumonia. The major defense mechanisms include airway barriers such
as the epiglottis, cough reflexes, mucus, and mucociliary clearance (Safder et al., 2005).
Mucosal ciliary move bacteria up and out of the bronchioles and a cough reflex assists
this process. Additionally, the cellular and humoral immune systems help to eradicate
potential pathogens on a cellular and extracellular level, respectively. In the mechanically
ventilated patients, however, multiple factors compromise the body’s natural defenses
such as critical illness, comorbidities, and malnutrition thereby impairing the immune
system. Furthermore, endotracheal intubation blocks the cough reflex and mucociliary
clearance, injures the tracheal epithelial surface, and provides a direct passage of bacteria
into the lower respiratory tract (Safder et al., 2005).
Pathophysiology of VAP
Normally, the lower respiratory tract is sterile whereas pneumonia is an infection
in the lungs that causes the air sacs, or alveoli, to fill up with fluid or pus. The major
routes of VAP are from oropharyngeal colonization, from the stomach related to
secondary colonization, or from endotracheal-tube (ETT) biofilms (Safder et al., 2005). A
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biofilm is a collection of microbes that form an extracellular matrix or “slime” that traps
bacteria or fungus and can lead to an infection (Bonez et al., 2013). The mechanical
process of intubation alone facilitates microbial entry into the lungs by disrupting the
body’s natural defense between the oropharynx and trachea allowing micro-aspiration.
Critically ill patients may have a depressed level of consciousness further compounding
the decreased gag reflex and pooling of secretions. Intubated patients are also at increased
risk for the buildup of dental plaque and biofilms, which can harbor respiratory
pathogens. This plaque accumulation may create an environment that allows for the
adherence of organisms such as pseudomonas aeruginosa (Berry et al., 2011). The
positive pressure from the ventilator then propels oral contaminants forward into the
lungs.
Diagnosis of VAP
One of the significant challenges in diagnosing VAP is that there is no recognized
diagnostic gold standard, leading to both under and over diagnosis. Many conditions in
an intubated patient such as congestive heart failure or sepsis can mimic signs and
symptoms of VAP as well as how they appear on imaging. As a result, this may interfere
with correct and timely diagnosis (Kollef, 2018).
Ventilator-associated pneumonia is currently a clinical diagnosis made with a new
or progressive lung infiltrate on imaging that coincides with clinical signs and symptoms
of infection (i.e. leukocytosis, purulent secretions, and fever) as well as a positive
pathogen from a respiratory sample (Kollef, 2018). Pneumonia is considered a VAP
when it occurs more than 48-72 hours post endotracheal intubation. With the presence of
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radiologic infiltrates and two clinical criteria, the sensitivity of diagnosing VAP is 69%
and the specificity is 75% (Amanullah, 2015).
Healthcare providers rely upon radiographic, clinical, and laboratory indicators to
diagnose VAP and initiate empiric antibiotics. Some of these have been combined into
clinical diagnostic models, the most popular of which is the Clinical Pulmonary Infection
Score (CPIS). This tool was developed to facilitate the diagnosis of VAP based on points
assigned for each of the following signs and symptoms of pneumonia: tracheal secretions,
temperature, white blood cell (WBC) count, oxygenation, chest radiograph, and tracheal
aspirate culture. A score of > 6 indicates a VAP is more likely.
A systematic review and meta-analysis by Fernando et al., 2020 sought to
characterize and compare the accuracy of physical examination, chest radiography,
endotracheal aspirate (ETA), bronchoscopic sampling cultures, and CPIS > 6 to diagnose
VAP. Researchers included 25 studies totaling 1639 patients. Inclusion criteria included:
English-language articles through 2019, retrospective and prospective observational
studies, RCTs, adult intensive care unit (ICU) patients ≥ 16 years, and invasive
mechanical ventilation ≥ 48 hours. Additionally, the studies must have evaluated one or
more of the following characteristics: fever (defined as body temperature ≥ 38 degrees
Celsius), purulent secretions, leukocytosis (any threshold), chest radiography, gram stain
and/or culture from the lungs, or CPIS for diagnosis of VAP. Histopathological analysis
from lung biopsy and bronchoalveolar lavage (BAL) were the primary and secondary
reference standards, respectively. The two researchers independently extracted data and
assessed study quality.
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Fernando et al. (2020) found that none of the clinical diagnostic methods used to
diagnose VAP were very accurate. The pooled sensitivity and specificity of physical
examination findings for VAP were poor: fever (66.4% [95% CI: 40.7–85.0], 53.9%
[95% CI 34.5–72.2]) and purulent secretions (77.0% [95% CI 64.7–85.9], 39.0% [95%
CI 25.8–54.0]). An infiltrate on chest radiography had a sensitivity of 88.9% (95% CI
73.9–95.8) and specificity of 26.1% (95% CI 15.1–41.4). ETA had a sensitivity of 75.7%
(95% CI 51.5–90.1) and specificity of 67.9% (95% CI 40.5–86.8). Protected specimen
brush bronchoscopy (PSB) had a sensitivity of 61.4% [95% CI 43.7–76.5] and specificity
of 76.5% [95% CI 64.2–85.6]; while BAL had a sensitivity of 71.1% [95% CI 49.9–85.9]
and specificity of 79.6% [95% CI 66.2–85.9]. CPIS > 6 had a sensitivity of 73.8% (95%
CI 50.6–88.5) and specificity of 66.4% (95% CI 43.9–83.3). The findings were consistent
when using either reference standard.
The presence of infiltrate on chest radiography had the highest sensitivity of
88.9% but had poor specificity. The CPIS was deemed inaccurate by researchers
regardless of the reference standard used. This meta-analysis suggests that the methods
clinicians routinely use to diagnose VAP and initiate antibiotics in the ICU are neither
sensitive nor specific.
The study has some limitations; it does not include the sensitivity and specificity
of histopathology from lung biopsy and this was the reference standard utilized
suggesting it is most accurate. They did state it was impractical for routine diagnosis, and
that results may be influenced by the area of the lung that is biopsied. The study used
published data so not all details of subjects included may have been known as well as if
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patients were on antibiotics prior to bronchoscopic sampling, both of which may
confound the results.
Consequences of VAP
Ventilator-associated pneumonia is correlated with increases in mortality, length
of stay, and exponential increases in health care costs. A patient with VAP remains in the
ICU 4 to 19 days longer than patients who were intubated and did not acquire a VAP.
This longer stay is associated with higher costs. The cost of care for a patient with VAP is
approximately $40,000 to $57,000 higher than the cost for a patient on mechanical
ventilation without VAP (Sedwick et al., 2012). The mortality rate for VAP ranges from
27-76% (Amanullah, 2015).
VAP Bundles
The 100,000 Lives Campaign was a nationwide initiative launched by the Institute
for Healthcare Improvement (IHI) in 2006 with a goal to reduce morbidity and mortality
in health care in the United States. The campaign focused on six key areas for
improvement including: initiating rapid response teams; acute myocardial infarction
interventions; preventing adverse drug reactions; preventing central line infections;
preventing surgical site infections; and preventing VAP (IHI, n.d.).
The IHI recommends VAP bundles, which are evidenced-based interventions, to
improve patient outcomes. The VAP bundle originally included: elevation of the head of
bed between 30 and 45 degrees, daily sedation interruptions, daily assessment of
readiness to extubate, stress ulcer prophylaxis, and deep vein thrombosis prophylaxis. In
the spring of 2010, after new clinical trials were examined, oral care with chlorhexidine
0.12% was added to the bundle.
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Recent evidence has challenged the VAP bundle and added further up to date
recommendations on interventions. “Strategies to Prevent Ventilator-Associated
Pneumonia in Acute Care Hospitals: 2014 Update” was published to update the 2008
guidelines to include the new recommendations of the use of subglottic secretion
drainage ports for patients likely to require intubation >48 hours and only changing the
ventilator circuit as needed rather than on a fixed schedule. The subglottic suction drains
potential pathogens that pool above the ETT. The humidified gas in the ventilator circuit
is at increased risk for contamination with frequent manipulation and would have direct
entry through the ETT into the lungs. The new guidelines also do not recommend the use
of stress ulcer prophylaxis as it did not have an impact on VAP rates (Klompas, Branson,
Eichenwald, et al., 2014). The Intensive Care Society (ICS) and the National Institute for
Health and Care Excellence (NICE) recently withdrew its recommendation for the use of
oral chlorhexidine in non-cardiac surgery patients in 2016 after a new meta-analysis
suggested its association with an increase in mortality (Hellyer et al., 2016). The exact
mechanism resulting in higher mortality rates remains unclear, but it may be that some
patients aspirate chlorhexidine and develop acute respiratory distress syndrome (ARDS)
(Price et al., 2014).
Although many medical experts believe that the campaign has been a success, the
IHI has not been able to accurately calculate and quantify the data (IHI, n.d.). A
systematic review by Lawrence and Fulbrook (2011) examined the impact of VAP
bundles on the incidence of VAP. Inclusion criteria included English language
experimental studies between 2004-2009, clinical outcomes measured, and studies that
included head of the bed minimum of 30 degrees, daily sedation holiday, gastric ulcer
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prevention, and DVT prophylaxis. Ten studies were included in the review. Three of the
studies had chlorhexidine mouth care as a bundle component. The studies included were
observational with no control group because the researchers deemed it unethical to not
implement the IHI’s recommendation for the bundle. Therefore, the researchers could not
definitively conclude a causal relationship between the bundle implementation and
incidence of VAP; however, there was a positive association.
Chlorhexidine and Oral Care
Oral CHG is a prescribed antiseptic that reduces microbial colonization in the oral
cavity. It covers a broad spectrum of microorganisms including gram-positive bacteria,
gram-negative bacteria, and yeast. A 0.12% concentration is currently the only oral
formulation approved by the Food and Drug Administration (FDA) for use in the United
States (Grap et al., 2017). This germicidal rinse is typically used to treat gum disease such
as gingivitis and periodontitis in adults. It has been adopted into oral care protocols up to
twice daily for mechanically ventilated patients to decrease the pathogen load in oral
plaque and the risk of VAP.
The technique of applying CHG during oral care is done by rinsing the mouth
with a CHG solution using a sponge or toothbrush followed by oral suction; generally, a
suction catheter kit that has a toothbrush or sponge is used. Some manufacturers sell
commercially packaged “24-hour systems” which include all-inclusive kits with
individually packaged products to use every two to four hours for mouth care. The kits
may include mouth moisturizer for every two to four hours and chlorhexidine solution for
twice daily oral care (Q•CareOral Cleansing & Suctioning Systems, 2018). Many
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hospitals are utilizing these kits; however, there are no universal protocols for continuity
between hospitals on exact mouth care procedures and products used.
A prospective, randomized, double-blind, placebo-controlled clinical trial by
Ćabov et al. (2010) included a total of 60 intubated patients in a surgical ICU in Croatia
assessed whether oral CHG mouth care impacted dental plaque, colonization of the oral
cavity, and nosocomial infections. The control group received standard oral care, which
consisted of rinsing the mouth with bicarbonate isotonic solution and gentle
oropharyngeal sterile suctioning followed by the application of a placebo gel. The
experimental group received the same standard care with the addition of a 0.2%
chlorhexidine gel rubbed on the teeth by a gloved finger of a nurse three times daily.
Dental status, plaque samples, nasal and tracheal aspirates, and urine samples were
obtained 24 hours after admission and then every three days until discharge. Dental status
was assessed using the caries-absent-occluded (CAO) dental index which is calculated as
the sum of decayed, missing, and filled teeth and ranges from 0 (normal dental status) to
28 (all teeth absent or decayed). The study found that 63% of patients had preexisting
colonized dental plaque and oral mucosa with multiple aerobic organisms on admission.
Moreover, they found a positive correlation between colonized dental plaque and the
development of numerous nosocomial infections such as bacteremia, UTI, or VAP. The
rate of these nosocomial infections was four times lower in the group receiving the
chlorhexidine oral care. The most frequently acquired nosocomial infection was
pneumonia, with a statistically higher rate of occurrence in the placebo group. More
specifically, the number of cases of pneumonia was significantly higher in the placebo
group (6/30) than the chlorhexidine group (1/30) (p=0.039) (Ćabov et al., 2010). The
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number of patients being admitted colonized with pathogens that cause VAP paired with
the positive correlation of chlorhexidine reducing infection rates, supports the theory that
chlorhexidine oral care prior to intubation may impact and potentially reduce VAP rates.
The study had some notable limitations. The sample size was small, having only
60 patients, which decreases the power of the study’s results. The study also did not
compare the differences in infection rates between the patients that came in with
colonization versus those that did not. Patients were first randomized into a group by
computer generation then swabbed for colonization on admission after being assigned a
group. However, the researchers stated there was no statistical differences in bacterial
colonization of dental plaque (P = 0.21) or buccal mucosa (P = 0.42) between the groups
on day 0.
CHG and the Prevention of VAP in Mechanically Ventilated Patients
Saliva acts as a lubricant to the oral cavity and provides antibacterial and
buffering properties in healthy patients. Mechanically ventilated patients may lack saliva
related to side effects from the multiple medications they are receiving and prolonged
mouth opening related to the ETT (Hua et al., 2016). Regularly scheduled oral care is
intended to mimic the function of the saliva by moistening the mouth as well as removing
debris and plaque (Hua et al., 2016). Using an antiseptic such as CHG, may further
reduce the bacterial burden or delay a subsequent increase in bacterial burden (Hua et al.,
2016). Decreasing the bacterial burden from the oral cavity would reduce the opportunity
of bacteria being aspirated into the respiratory tract and causing a VAP plaque (Hua et al.,
2016).
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A systematic review by Hua et al. (2016) analyzed 38 randomized controls trials
comparing four main groups of interventions (CHG mouth rinse vs. placebo,
toothbrushing vs. no toothbrushing, powered toothbrush vs. oral care with manual
toothbrush, oral care with other solutions) in the oral hygiene care of critically ill patients
receiving mechanical ventilation for at least 48 hours in intensive care units. The 18
RCTs that compared CHG versus placebo used concentrations 0.12%, 0.2%, 1%, and 2%.
The study found the use of chlorhexidine reduced the risk of VAP compared to placebo
from 24% to 18% (P = 0.004). There was no evidence that use of CHG was associated
with a difference in mortality, duration of mechanical ventilation or duration of ICU stay.
There were some limitations in this systematic review including the potential bias
in the variation and subjective nature of criteria used for VAP diagnosis per each study.
This makes it difficult to compare VAP results when different diagnostic tools were used
to define VAP. Also, the specific details of what was involved in the oral hygiene care
intervention were poorly described in some of the studies.
Klompas, Speck, Howell, et al. (2014) conducted a systematic review and metaanalysis of 16 RCTs examining the use of CHG versus placebo on the incidence of VAP.
Researchers sought to reappraise the evidence after noting bias in previous systematic
reviews. Previous reviews included studies with a majority of cardiac surgery patients
that were primarily extubated within 24 hours and that little distinction was made
between open-label versus double-blind investigations leading to bias in favor of CHG
use. Due to the lack of gold standard for the diagnosis of VAP the researchers chose to
compare duration of mechanical ventilation, length of stay, and mortality as more
objective patient-centered outcomes. Inclusion criterion was RCTs evaluating daily oral
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care with CHG (any preparation) versus a placebo in adult patients receiving mechanical
ventilation. Data bases were searched without date restrictions and previously published
meta-analyses and the reference lists of all suggestive articles were reviewed for
inclusion. Cardiac surgery studies accounted for 51% of patients and non–cardiac surgery
investigations included 49% of patients in this review.
The results indicated there were fewer lower respiratory tract infections in cardiac
surgery patients receiving chlorhexidine (relative risk (RR), 0.56; 95% confidence
interval (CI), 0.41-0.77) but no significant difference in VAP in noncardiac surgery
patients (RR, 0.88; 95% CI, 0.66-1.16). There was no significant difference in mean
duration of mechanical ventilation or intensive care length of stay in either groups. There
was a nonsignificant result of increased mortality with chlorhexidine use among non–
cardiac surgery studies. Limitations included the pulmonary outcomes in the cardiac
surgery studies were specified as “nosocomial pneumonia,” “upper respiratory tract
infections,” “lower respiratory tract infections,” or “total respiratory tract infections”
(Klompas, Speck, Howell, et al. 2014), but in all non–cardiac surgery studies the
outcomes were defined as VAP. No further definitions were given as to what criteria
were used to diagnose these.
Deschepper et. al. (2018) conducted a retrospective, observational cohort study
including 82,274 patients hospitalized in various settings in Belgium with the objective of
assessing the effect of CHG oral care on mortality. Oral care with 15 mL 0.05% or 0.12%
CHG was given twice daily on general wards and three times daily to ICU patients. A
proxy measure for CHG exposure was defined as low ≤ 300 mg or high > 300 mg,
respectively. Independent patients were given instructions to swish and spit and
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dependent patients had oral swabbing provided by nurses. This two-year study included
patients 16 years or more with adjustment for risk of mortality and severity of illness
based on the All Patient Refined-Diagnosis Related Groups (APR-DRG). Patients
without APR-DRG risk of mortality were excluded as well as childbirth related
admissions.
A total of 14% of patients hospitalized and discharged between 1 January 2012
and 31 December 2014 that met inclusion criteria received CHG oral care during their
hospitalization, either in a solution of 0.05% (n = 1175) or 0.12% (n = 9963). The study
found no association between CHG oral care and increased mortality in postoperative
cardiothoracic and vascular surgery patients or patients receiving mechanical ventilation.
In cardiothoracic and vascular surgery patients the relationship between CHG oral care
and mortality did not reach statistical significance (CHG exposure ≤ 300 mg odds ratio
(OR) 0.96; 95% CI 0.60–1.55; P = 0.874, CHG exposure > 300 mg OR 1.43; 95% CI
0.88–2.32; P = 0.146). CHG oral care was associated with increased risk of death in
patients who were not admitted to the ICU and those that did not receive mechanical
ventilation. Overall, the patient’s with better prognosis on risk assessment for mortality
was associated with a greater chance for adverse effects related to CHG oral care.
The study has several limitations including its observational design which is
prone to bias. Also, it is unclear why there were two different doses (0.05% and 0.12%)
of CHG, why one was indicated over the other, and why only 14% of patients included in
the study received CHG oral care during their hospitalization. This is a small percentage
of their sample size and is the purpose of the study. Perhaps more strict inclusion criteria
were required to yield a higher percentage. The lack of a tangible pathogenic mechanism
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leading to increased risk of mortality leaves the data difficult to interpret. The study
proposes micro-aspiration of CHG leading to ARDS or anaphylactic reactions as
potential links to increased mortality but states further research is indicated with these
outcome criteria.
Varying evidence supports the use of chlorhexidine in select populations and it is
being utilized in ICUs throughout the United States, but little research has been done to
study when chlorhexidine should be initiated. Given that there is some evidence that
CHG use decreases VAP rates and that intubation is a risk for infection, it could be
hypothesized that the use of oral chlorhexidine prior to intubation would decrease VAP
rates.
Chlorhexidine Prior to Intubation and VAP Prevention
As previously discussed, the process of intubation is a risk factor for VAP as the
ETT passes through the microbe rich oropharynx and down into the lungs. In most other
invasive clinical procedures where a tube is inserted, decontamination procedures are
done at the insertion site to reduce the risk of colonization or infection. For example,
prior to a urinary catheter insertion the meatus is scrubbed with an antiseptic.
Endotracheal intubation usually proceeds without any preparation of the mouth other than
the removal of dentures and potentially suctioning of oral secretions. The use of oral
chlorhexidine prior to intubation could potentially eliminate the risk of introducing
microbes from the oral cavity into the lungs during the intubation procedure (Munro et
al., 2015).
Nicolosi et al. (2014) conducted a quasi-experimental study to test this
hypothesis. The study took place in a large hospital in Argentina and included patients
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undergoing cardiothoracic surgery. The control and experimental group each included
123 patients. The control group received the hospital’s standard preoperative protocol of
mupirocin antibiotic nasally for three days prior to surgery, administration of a thirdgeneration cephalosporin 30 minutes before and after surgery, and continuation of the
patient’s normal oral routine prior to admission. The experimental group received the
same treatment with the addition of 0.12% CHG every 12 hours for three days
preoperatively with education on proper tooth brushing techniques by a dentist. The
measurable outcome was the development of VAP. The group that received oral
decontamination preoperatively with chlorhexidine had a VAP rate of 2.7% while the
control group had a rate of 8.7% demonstrating the risk of developing VAP after surgery
was more than 3 times greater in patients who did not receive oral decontamination with
chlorhexidine. Study limitations include its small sample size and its quasi-experimental
design.
A similar prospective intervention study by Bergan et al. (2013) tested the same
hypothesis including 226 patients undergoing cardiothoracic surgery at a federal public
hospital in Brazil. Patients received education from a dentist on proper tooth brushing
techniques and were instructed to rinse their mouth and gargle with CHG 0.12 % twice a
day for 2 minutes and just prior to the operating room. Postoperatively, the nurses
performed the toothbrushing and CHG oral care. The measurable outcome was diagnosis
of VAP. All patients received two grams of cefazolin 30 minutes before cardiac surgery
as standard preoperative prophylaxis. Prior to the implementation of the CHG, the VAP
rate was 32 per 1,000 (3.2) ventilator-days; the rate declined to 10 per 1,000 (1)
ventilator-days within one year of the start of the new protocol. The hospital had a 69%
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reduction in the incidence of VAP by 12 months. This is significant since the study also
found the presence of pneumonia increased the chances of death by 11 times, P < 0.0001.
Mortality in patients with pneumonia was 6/19 (33.3 %) versus 9/208 (4.32 %) in those
without pneumonia. Limitations include small sample size and being a single center study
in the setting of a developing country. The study does speculate that cardiac surgery
patients at their institution have lower postoperative pneumonia rates related to their
regular referrals for dental care preoperatively to prevent endocarditis.
There are limited randomized control trials investigating the use of oral
chlorhexidine prior to intubation and the impact on the incidence of VAP. Four published
studies meet inclusion criteria of this systematic review.
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Theoretical Framework
Louis Pasteur proposed the germ theory in 1858 theorizing that specific organisms
are capable of causing infectious diseases. This simple cause and effect theory has been
critical to the development of modern medical care and its impact has helped to
drastically decrease the number of deaths from infection (Mcewen & Wills, 2011).
Pasteur’s theory is predominantly utilized in disease prevention and epidemiological
studies. The theory seeks to identify, understand, and manage infectious diseases leading
to the development of ways to prevent and treat disease.
This systematic review utilizes the principles of Pasteur’s germ theory. During the
literature review, the problem of VAP was identified and explored. Causative
mechanisms were further investigated with intubation and biofilms identified as leading
factors. Methods to prevent VAP were explored specifically focusing on chlorhexidine
mouth care prior to intubation.
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Methods
A systematic review was conducted to determine if the use of oral care with
chlorhexidine prior to intubation impacts the incidence of ventilator-associated
pneumonia. The Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) was used to guide the selection process of articles and the Critical Appraisal
Skills Programme (CASP) was used to critically appraise the randomized control trials
selected for this systematic review. The ethical considerations for this systematic review
are that PRISMA, as well as the inclusion and exclusion criteria, were strictly followed.
Using the PRISMA checklist (Appendix A) and the flow diagram (Appendix B), a
comprehensive literature search for RCTs was performed using the databases CINHAL,
Google Scholar, and Medscape and combining the key terms: ventilator-associated
pneumonia; chlorhexidine; oral care; and prior to intubation. The inclusion criteria
included randomized control trials, age greater than 18 years, and receiving oral
chlorhexidine prior to being intubated. The study had to compare the use of chlorhexidine
mouth care prior to intubation versus not using chlorhexidine prior to intubation and the
incidence of VAP had to be the measurable outcome. Only articles published in English
were reviewed. Exclusion criteria were randomized control trials that did not use
chlorhexidine prior to intubation, participants less than 18 years old, non-English
language articles, studies that were not randomized control trials, and studies that did not
have VAP as the measurable outcome. Literature was searched initially from 2006 to
2020 and then with no date restriction using the above-mentioned inclusion and exclusion
criteria related to the limited number of RCTs available on this topic.
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PRISMA consists of a 27-item checklist (Appendix A) and a four-phase flow
diagram (Appendix B) that dictates the steps of the evaluation of each study and in turn
allows for presentation of the information in a precise and consistent manner. The
checklist includes the major sections of a systematic review and what is to be included in
each section. These sections include the major categories of title, abstract, introduction,
methods, results, and funding (Moher et al., 2009). There are also several subcategories
within each section. The PRISMA checklist was utilized to ensure data extracted from
each of the included randomized control trials was complete and consistent.
The four-phase flow diagram (Appendix B), including identification, screening,
eligibility, and inclusion, was used to select the articles appraised for the systematic
review (Moher et al., 2009). Identification involves identifying records through databases
and other sources. Screening involves refining the search to only pertinent studies related
to the specific research question at hand and eliminating any duplicates that occur. The
eligibility phase uses inclusion and exclusion criteria to omit any studies that do not meet
criteria and includes an explanation of why. Lastly, the inclusion phase is the final
number of studies that will be used in the systematic review. Using this four-phase
process, studies were identified, screened for duplicates, and assessed for eligibility,
which resulted in a select number of studies to be used in this systematic review.
Once the randomized control trials were selected, each article was analyzed and
pertinent data was presented in an organized table (Appendix C1-4) allowing for
comparison of the studies’ purposes, designs, sites and samples, methods, results, and
limitations. Each randomized control trial was then critically appraised using the CASP
checklist for RCTs to determine the studies’ scientific integrity (Appendix D1-4).
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The CASP is part of the Oxford Centre for Triple Value Healthcare and strives to
systematically assess the trustworthiness, relevance, and results of published papers. The
CASP checklist for randomized control trials is an 11-question standardized checklist to
methodically determine the quality, validity, and integrity of a study (CASP, 2018).
Lastly, a cross study analysis (Appendix E1-4) was performed to compare the
placebo used in each study, the CHG dose selected, and the effect on incidence of VAP.
The similarities and differences between the studies were compared.
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Results
Search Results
The search terms yielded 236 results; 62 duplicates were eliminated leaving 174
remaining for review. The abstracts were then reviewed to determine if they met
inclusion and exclusion criteria; 16 articles remained. The full texts of the remaining
articles were read and assessed for the inclusion/exclusion criteria, leaving a total of 4
articles that were used in this systematic review. Pertinent data from each article was
organized into data a table (Appendix C). Next, each study was summarized as follows
and the studies were critically appraised using the CASP checklist (Appendix D).
Study Characteristics
A randomized control trial by Munro et al. (2015) (Appendix C1) evaluated the
benefit of adding a preintubation CHG dose to the hospital’s standard postintubation
CHG to reduce the risk of VAP. Prior to intubation, study personnel swabbed the oral
cavity with 5 mL of a 0.12% CHG. Postintubation, the same dose and concentration of
CHG was administered by the responsible nurse on a twice daily schedule until
extubation. A secondary aim was to test the effect of a preintubation oral application of
CHG on early endotracheal tube (ETT) colonization. The RCT included 314 subjects
from two large Southern urban teaching hospitals in the United States. Immediately prior
to intubation, subjects were recruited from multiple clinical areas, including critical care
units, emergency departments, preoperative areas, procedural areas, and medical surgical
units during rapid response or code calls. The CHG group was 58% male with a mean
age of 58.1 years and a mean Acute Physiology and Chronic Health Evaluation
(APACHE) score of 69.1. The control group consisted of 62% males with a mean age of
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58.2 years and a mean APACHE score of 65.1. Patients with a clinical diagnosis of
pneumonia at the time of intubation were excluded.
Subjects were randomly assigned to the intervention group that received oral
application of 5 mL 0.12% CHG by oral swab or the control group that received no
preintubation intervention. All subjects received CHG twice a day after intubation as
standard of care. The Clinical Pulmonary Infection Score (CPIS) was used to evaluate the
risk of VAP with a VAP threshold score of > 6. Any score > 6 signified an increased risk
for VAP. Researchers chose the CPIS to evaluate the risk of early-onset VAP because it
permitted serial prospective evaluation of VAP risk without substantially increasing risks
to human subjects. A swab was taken of the distal ETT after extubation to assess the
secondary aim of ET colonization.
The results of this study (Appendix E1) demonstrated no statistically significant
improvement in CPIS scores from the CHG group over the control group. The mean
CPIS scores from both groups remained below the VAP threshold of 6 signifying a VAP
was not likely. Regarding the study’s secondary aim of ETT colonization occurrence, the
majority of ETTs in both study groups were not colonized at the time of extubation
(81.4% in the CHG group and 82.5% in the control group). There was no statistically
significant difference in ETT colonization between the groups (P = 0.8656).
Critical analysis of the Munro et al. (2015) study using the CASP checklist
(Appendix D-1) revealed both groups were statistically similar. Although the sample size
was small, a priori power analysis was used to determine the sample size required to
detect a difference in CPIS of 1 between the two groups. The clinical providers were
blinded to study group assignment, as well as the clinical laboratory personnel who
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performed microbial analyses and the coinvestigator who evaluated the chest x-rays. This
study had several limitations. Nine subjects in the CHG group did not receive the
intervention and the study does not explain why. Furthermore, there were four subjects
listed as “other” that did not remain in the intervention group and eight that did not
remain in the control group without rationale as to why. The study reported most subjects
were extubated prior to the full 5-day intervention period leading to unavoidable attrition
over the course of the study. There was no mention of a standard mouth care swabbing
technique or training to ensure continuity and it was being performed by hospital nurses
not study personnel. The possibility of data entry error exists due to the possibility that
CHG administration was recorded but not actually performed. The CPIS score used as a
diagnostic tool for VAP in the study only had a sensitivity of 73.8% and specificity of
66.4% (Fernando et al., 2020). Lastly, it is not made clear how randomization was
achieved or what additional inclusion criteria was used besides prior to intubation without
an existing diagnosis of pneumonia.
Houston et al. (2002) tested the effectiveness of 0.12% CHG oral rinse compared
to the standard control of phenolic mixture (Listerine) in decreasing microbial
colonization of the respiratory tract and hospital-acquired pneumonia in patients
undergoing open heart surgery. A total of 561 patients undergoing aortocoronary bypass
or valve surgery requiring cardiopulmonary bypass were randomized to an experimental
(n = 270) or a control (n = 291) group. The CHG group was 73% male, and the Listerine
group was 79% male. Patients were excluded from the study if they died during surgery,
were pregnant, or had a documented or patient reported preoperative respiratory
infection. Patients were randomized by medical record numbers. Preoperatively, both
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groups received 15 mL of their respective oral rinse to swish and spit and postoperatively
received the same by mouth swab twice daily until extubation, tracheostomy, death, or
diagnosis of pneumonia. Both groups received preoperative and perioperative
prophylactic antibiotics as part of the routine cardiac surgery protocol. Sputum samples
were collected every 48 hours until extubation. VAP was diagnosed using criteria
established by the Centers for Disease Control and Prevention.
Results of this study (Appendix E-2) revealed that VAP rates did not differ
significantly (4/270 vs. 9/291; P=0.21) in the CHG group compared to the Listerine
group. The study also found that only patients intubated for more than 24 hours
developed pneumonia (0/486 vs. 13/75; P = 0.01). The pneumonia rate was reduced by
58% (4/19 vs. 9/18; P = 0.06) overall in patients treated with CHG who were intubated
for more than 24 hours and had sputum cultures that showed positive microbial growth.
In patients at highest risk for pneumonia (intubated > 24 hours, with sputum cultures
showing the most growth), the rate was 71% lower in the CHG group than in the
Listerine group (2/10 vs. 7/10; P =.02).
Critical analysis of the Houston et al. (2015) study using the CASP checklist
(Appendix D-2) showed the two groups did not differ significantly in characteristics.
None of the patients extubated within hours of surgery developed pneumonia. Most
patients included in this study were extubated within hours of surgery, therefore, a
limitation may be the relatively small sample size. However, the sample size of 600 was
projected based on the hospital’s historical rate of VAP and was deemed sufficient to
detect a 0.20 effect size with 99% power. Perhaps the biggest limitation of the study is
that the researchers did not disclose whether the participants or providers were blinded.
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Age ranges of participants were not included. The study does not state how many doses
of oral rinse patients received in total preoperatively. There also could be error in selfreporting of the preoperative doses that patients did independently at home. Some doses
may have been skipped and not reported. The study refers to attrition resulting from death
and tracheostomy. However, it is not disclosed how many patients were properly
accounted for at the conclusion of the study.
DeRiso et al. (1996) examined whether twice daily preoperative use of 0.12%
CHG oral rinse reduced hospital-acquired infection rates in patients undergoing open
heart surgery in a prospective, randomized, double-blind, and placebo-controlled study.
Of the 353 patients who were included, 173 patients were randomized to the CHG group
and 180 to the placebo group. The CHG group was 69% male with the mean age of 64.1
years and the control group was 68% male with the mean age of 63.5 years. The chemical
make-up of the base solution of both the intervention and placebo oral rinses was similar;
the placebo had no antimicrobial properties. Each group received their respective oral
rinse twice daily preoperatively with an unspecified number of doses and postoperatively
twice daily until discharge from the ICU or death. Prophylactic antibiotics and
intravenous ranitidine were given as standard postoperative care. Exclusion criteria were
intraoperative death, preoperative infection or intubation, pregnancy, heart and lung
transplant recipients, and known hypersensitivity to CHG. The patients who failed early
extubation received tracheal aspirate culture at 48 hours and then every two days until
discharge from the ICU or death. This study also used the CDC’s diagnostic infection
criteria for VAP. Outcomes measured were overall rates of nosocomial infections, upper
and lower respiratory tract infections, urinary tract infections, fungemias, central line
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infection rates, wound infections, blood infections, other infections, nonprophylactic IV
antibiotic use, length of stay (LOS) in the hospital, duration of intubation, need for
reintubation, and in-hospital mortality.
Study results pertinent to this review (Appendix E-3) demonstrated an overall
decrease in all hospital-acquired infection rates in the CHG treated patients by 65% (P
<0.01). Total respiratory tract infections were 69% less common in the CHG treated
group (P<0.05) and the use of nonprophylactic IV antibiotics was lowered by 43%
(P<0.05). Although they found no statistical differences between the two groups
regarding average duration of mechanical ventilation, reintubation rate, or length of stay
in the hospital, there was a reduction in mortality in the CHG group versus control group
(1.16% vs. 5.56% respectively).
Critical appraisal (Appendix D-3) of the DeRiso et al. (1996) study using CASP
revealed it was unclear whether all patients that entered the study were accounted for at
the end of the study. Researchers also did not state why they chose the sample size they
selected; however, the sample that was selected did not statistically differ in
characteristics. The trial did clearly address the focus issue and the randomized doubleblind placebo-controlled design gives the study further validity.
Lin et al. (2015) investigated the effect of preoperative 0.2% CHG on
postoperative VAP rates. Patients that met inclusion criteria were selected prior to cardiac
surgery at a medical university hospital in China. Inclusion criteria were consciousness;
age >18 years; ability to independently gargle in the oropharynx; and requiring
orotracheal intubation and mechanical ventilation. The exclusion criteria were pneumonia
before intubation; history of previous heart surgery and intubation; or severe brain, liver,
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or kidney disease. Of the 94 patients that met the inclusion criteria, 47 were randomized
to the CHG group and 47 to the control group. All patients were blinded to their
grouping.
The day prior to surgery the CHG group gargled with 50 mL 0.2% CHG 30
minutes after all meals and 5 minutes after brushing teeth at bedtime. CHG was gargled
for 30 seconds and was repeated three times at one-minute intervals while the control
group gargled with normal saline adhering to the same schedule. Postoperatively, as part
of standard care while on mechanical ventilation, both groups had oral rinses with 50 mL
of 0.2% CHG, four times a day. After extubation, they were each required to gargle once
with 50 mL of 0.2% CHG then once after each meal for three days. The oral care of all
patients was performed by the same two trained healthcare professionals who were
blinded to the patients grouping. The outcome of VAP was diagnosed using the
simplified Clinical Pulmonary Infection Score (CPIS) and was assessed on days 1, 3, 5,
and 7 after intubation with a threshold of ≥ 6. Patients with CPIS ≥ 6 and < 6 were
classified as those with and without VAP, respectively.
Results of the study (Appendix E-4) revealed that preoperative CHG mouthwash
reduced the incidence of postoperative VAP significantly; VAP occurred in 8.5% of the
chlorhexidine group and 23.4% in the control group (P = 0.049). CPIS scores were not
different between the two groups on postoperative day one; however, they were
significantly lower in the CHG group on the third (P = 0.024) and fifth (P = 0.005) day
when compared to the controls.
Critical analysis of the Lin et al. (2015) study using the CASP checklist
(Appendix D-4) revealed the study clearly addressed the focus of this review and met all
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criteria other than the small sample size of only 47 in each group. To achieve a power of
80% with a risk ratio of 0.36 over 90 patients would have been required in each group.
The ideal power of 80% means the study would have a high chance of detecting a
difference between the two groups. Since the study fell short of this goal without
explanation, caution should be used when drawing conclusions as to whether there was a
true difference between the two groups. The researchers had used a prior study to
estimate the group sizing, which was 98 in each group, so they still fell short based on
their initial needs assessment. This known small sample size is a limitation of the study.
Additionally, the preoperative rinse was to be used the day before surgery after meals and
before bed. This may lead to some patients receiving a different number of doses based
on how many meals were eaten that day. The total mL of preoperative CHG and saline
was not disclosed. Furthermore, self-reporting the correct use of four times a day
preoperative CHG oral rinse may have led to error related to inaccurate reporting from
patients. The study design is unclear with researchers stating 1:1 randomization by
computer generator followed by statements that the treating physician assigned the
groups the day before surgery. Lastly, the study does not make clear if the two trained
and blinded nurses performing oral care, data collection, and diagnosis of VAP were
from the researchers’ team or the hospital’s.
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Cross Analysis
A cross study analysis table (Appendix E) was created to compare the RCTs used
for this systematic review. The table includes which placebo was utilized, the CHG dose
and frequency of administration and the effect on incidence of VAP.
A different placebo and CHG dose were used in each of the four RCTs. Munro et
al. (2015) were the only researchers to investigate noncardiac surgery patients. They
included patients from multiple clinical areas of the hospital including those prior to
emergent intubations. The intervention group received 5 mL 0.12% CHG prior to
intubation while the control group received no CHG prior to intubation. The intervention
group received 5 mL 0.12% CHG by swab to the oral cavity administered by study
personnel prior to intubation while the control group received none. After intubation both
groups received 5 mL 0.12% CHG administered by the responsible nurse twice daily
until extubation. Houston et al. (2002) used 15 mL of Listerine brand phenolic mouth
rinse as the placebo. Each group received 15 mL of either the Listerine mixture or 0.12%
CHG preoperatively (30 sec swish & spit) and twice daily postoperatively (30 sec swab)
for 10 days postoperatively or until extubation, tracheostomy, death, or diagnosis of
pneumonia. DeRiso et al. (1996) used a placebo with similar chemical makeup without
CHG or antimicrobial properties that had identical packing. Either the placebo or the
0.12% CHG was given twice daily preoperatively, however, the study failed to disclose
for how many days. Postoperatively 15 mL of either solution as an oropharyngeal rinse or
rigorously applied to the buccal, pharyngeal, gingival, tongue, and tooth surfaces for 30
seconds twice daily until discharge from the ICU or death. Lastly, Lin et al., 2015 used
0.9% saline solution as a placebo in the control group but did not specify the amount. The
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day prior to surgery, patients gargled three times with 50 mL 0.2% CHG or the saline
placebo 30 minutes after all meals and 5 minutes after brushing teeth at bedtime. Either
solution was gargled for 30 seconds and was repeated three times at one-minute intervals.
Once intubated both groups had oral rinse with 50 mL of 0.2% CHG four times a day.
Three of the four RCTs, Houston et al. (2002), DeRiso et al. (1996), and Lin et al.
(2015), showed an improvement in VAP rates with the use of preintubation CHG. Only
one RCT, the Munro et al. (2015) study, showed no benefit. There was no statistically
significant improvement in the CPISs from the CHG group over the control group and
both groups CPS scores remained less than the VAP threshold of 6. In regard to the
study’s secondary aim of evaluating preintubations impact on ETT colonization, both
groups were < 20% colonized with no significant difference (P = 0.8656).
There were some variances in the amount of total risk reduction among the other
three studies that found a reduction in VAP with the use of preintubation CHG. Houston
et al. (2002) found the overall rate of nosocomial pneumonia was reduced by 52% (4/270
vs 9/291; P =.21) in the CHG-treated patients. DeRiso et al. (1996) found VAP 69% less
common in the CHG-treated group compared to the placebo group (5/173 vs 17/180; p <
0.05). Lin et al. (2015) found an absolute risk reduction of VAP with the CHG group of
14.9% (23.4%/8.5%).
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Discussion
The previously discussed differences in the dosages and application techniques
may have influenced these varying results as well as many other factors that will be
discussed in the summary and conclusions section.
Ventilator-associated pneumonia is a major concern in hospitals that is correlated
with increases in mortality, length of stay, and exponential increases in health care costs
(Sedwick et al., 2012). In response to this, the IHI developed VAP bundles in 2006, which
are evidenced-based interventions to improve patient outcomes. The inclusion of oral care
with chlorhexidine 0.12% was made in the spring of 2010 after new clinical trials suggested
an improvement in VAP rates. There have been multiple changes to the bundle over the
years related to updated recommendations following new clinical trial. The ICS and NICE
withdrew its recommendation for the use of oral chlorhexidine in non-cardiac surgery
patients in 2016 after a new meta-analysis suggested its association with an increase in
mortality (Hellyer et al., 2016). There is limited research exploring the proper time to
initiate chlorhexidine. The purpose of this paper is to determine if the use of oral care with
chlorhexidine prior to intubation impacts the incidence of ventilator-associated pneumonia.
A comprehensive literature search for RCTs was performed using the databases
CINHAL, Google Scholar, and Medscape. The PRISMA 27-item checklist and four-phase
diagram (Moher et al., 2009) were utilized in the search process to ensure a thorough
selection of studies. This search strategy resulted in four RCTs meeting inclusion criteria
for this systematic review. Pertinent data from these studies were then organized into a data
collection table (Appendices C1-4) allowing for comparison of the studies’ purposes,
designs, sites and samples, methods, results, and limitations. The CASP checklist for RCTs
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was used for critically appraisal to determine the scientific integrity of each of the four
studies (Appendix D1-4). Lastly, a cross study analysis (Appendix E1-4) was performed
to compare the placebo used in each study, the CHG dose selected, and the effects of the
intervention variables on the incidence of VAP.
Three of the four RCTs, Houston et al. (2002), DeRiso et al. (1996), and Lin et al.,
(2015), showed an improvement in VAP rates with the use of preintubation CHG. Only
one RCT, the Munro et al., 2015 study, showed no benefit. This was the only study that
included non-cardiac surgery patients. Researchers did not perform any analysis on the
varying types of patients and the incidence on VAP. It is recommended that a secondary
analysis be done specific to cardiac surgery patients to see the impact of CHG application
on the incidence of VAP in this population. The Society of Thoracic Surgeons (STS)
promotes the practice of extubating patients within 6 hours after cardiac surgery as a quality
of care benchmark (Goeddel, Hollander & Evans, 2018) while other patient populations
requiring mechanical ventilation tend to remain intubated longer. The inclusion of other
patient populations in the Monroe et al. (2015) study may have negatively impacted results.
One of the significant challenges in diagnosing VAP is that there is no recognized
diagnostic gold standard or definition (Kollef, 2018) and the definition has evolved over
time. VAP is currently a clinical diagnosis therefore subjective to some extent varying from
provider to provider based on his or her interpretation. Fernando et al. (2020) found that
none of the clinical diagnostic methods used to diagnose VAP were very accurate. Some
of the radiographic, clinical, and laboratory indicators were combined into clinical
diagnostic models, the most popular of which is the Clinical Pulmonary Infection Score
(CPIS). This scale was also deemed unreliable by Fernando et al. (2020) with a sensitivity
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of 73.8% (95% CI 50.6–88.5) and specificity of 66.4% (95% CI 43.9–83.3). There were
differences in the four studies in the criteria used to diagnose VAP. The CPIS score was
utilized in the Lin et al. (2015) and Munro et al. (2015) while the CDC criteria was used to
diagnose VAP in the older RCTs DeRiso et al. (1996) and Houstan et. al (2002). Since
none of the clinical diagnostic methods used to diagnose VAP were reliable perhaps more
concrete primary outcomes such as mortality, duration of intubation, and antibiotic
utilization should be used.
Limitations
There were several limitations in this systematic review. Only four studies met the
inclusion and exclusion criteria which may affect generalizability. Also, all the RCTs were
relatively small with each including between 94-561 participants. Practice differences
related to ever changing standards of care plays a large factor in difficulties comparing the
RCTs. Some of the trials date back prior to the initiation of the bundles; DeRiso et al. was
published in 1996 and Houstan et. al in 2002, both well before the initiation of the IHI
bundle in 2006. Therefore only Lin et al., (2015) and Munro et al., (2015) included all
updates to the bundles to include elevation of the head of the bed to 30º to 45º; prophylaxis
for peptic ulcer disease; prophylaxis for deep-vein thrombosis; daily interruption of
sedation (sedation holiday); daily assessment of readiness for extubation; the use of
subglottic secretion drainage ports for patients likely to require intubation > 48 hours and
only changing the ventilator circuit as needed rather than on a fixed schedule as well as
daily oral care with chlorhexidine. Therefore, the bundle itself is a cofounder in the newer
studies since it may be responsible for some of the positive effects and CHG alone cannot
be held solely accountable.
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Another limitation with comparing studies is the differing concentrations of CHG
used. A 0.12% concentration is currently the only oral formulation approved by the Food
and Drug Administration (FDA) for use in the United States (Oral Care for Acutely and
Critically Ill Patients, 2017). Lin et al. (2015) was the only study to use a strength other
than 0.12%; researchers used 0.2% as the study was done in China where this concentration
is available. All other studies were performed in the United States.
Lastly, there is no worldwide standardized mouth care protocol. Each study had a
different method, duration, length of time and process for the administration of either the
placebo or the CHG. This may have further influenced the ability to fairly compare the
results.
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Summary and Conclusions
The results of this systematic review demonstrate the use of CHG prior to intubation
was effective in reducing the VAP rates in post-cardiac surgery patients in three of the four
studies included in this review. These findings are not generalizable, however, related to
the lack of large, randomized control trials including both cardiac and noncardiac patients.
It remains unclear as to most effective dosing, frequency, and application procedure of
CHG. The majority of patients in the studies were intubated for less than one week,
however, some studies did not disclose an exact number of days. There is no evidence
demonstrating a definitive time frame of CHG use related to length of intubation post
cardiac surgery. Also, now that oral CHG is not being utilized in non-cardiac ICU patients,
further studies of its use prior to intubation could be more accurate as they will not be
receiving the CHG after intubation. More research is needed to determine effective dosing,
frequency, and application procedures of CHG as well as exploring if it is safe to administer
CHG prior to intubation in noncardiac surgery patients.
Although there were several limitations in the RCTs and some differences made
them difficult to compare, the achievement of the primary aim in this systematic review
results in recommendations and implications that can be made for the advanced practice
nurse in the clinical setting.
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Recommendations and Implications for Advanced Nursing Practice
The role of the advanced practice nurse (APN) has evolved to meet the challenge
of access to health care across the United States. APNs have become an integral part of
healthcare teams in both the inpatient and outpatient setting. APNs utilize evidence-based
practice (EBP) methods to provide safe and efficient care to their patients. This
systematic review presents evidence-based findings that may guide APNs in making
informed decisions in future practice.
Based on this systematic review, it can only be recommended that cardiac surgery
patients receive CHG prior to and after intubation; however, more research needs to be
done to determine the effective dosing, frequency, and application procedures as well as
exploring if it is safe to administer CHG prior to intubation in noncardiac surgery
patients.
The results of this systematic review demonstrate the use of CHG prior to
intubation was effective in reducing the VAP rates in three of the four studies included in
this review; however, the three studies that did show an improvement only included
cardiac surgery patients. Munro et al., (2015) was the only study to include non-cardiac
surgery patients including emergent intubations and the results yielded no benefit with
the use of CHG and VAP. The ICS and the NICE withdrew its recommendation for the
use of oral CHG in non-cardiac surgery patients in 2016 after a new meta-analysis
suggested its association with an increase in mortality (Hellyer et al., 2016). Now that
oral CHG is not being utilized in non-cardiac ICU patients, further studies of its use prior
to intubation could be more accurate as they will not be receiving the CHG after
intubation. APNs are in a position to lead research projects and develop new EBP
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standards and implementation in clinical practice. In addition, they can develop safe
policies and educate staff on safe practices.
Further research is recommended. The next RCT trials to explore CHG prior to
intubation should have larger sample sizes and the controls should be double blind.
Utilizing different primary outcomes in these studies such as mortality, duration of
intubation, and antibiotic usage may be more effective in quantifying VAP occurrences
than the previously used ineffective CPIS scores. These outcomes may be more sensitive
regarding the impact of VAP since there remains no gold standard for diagnosing it.
The lack of a standardized approach to mouth care in the ICU setting was also
evident throughout this review. The APN has the ability to work closely with
interdisciplinary teams, including dentistry, to create one evidence-based, standard
approach to oral care in intubated patients. Creating such a procedure with a stepwise
approach would create continuity across ICUs worldwide.
The current healthcare environment focus is on delivering superior patient care
for less cost. Low expenditure preventative interventions such as oral care with CHG
could help reduce VAP rates and decrease mortality, length of stay, and costs. Ventilatorassociated pneumonia has a detrimental cost effect on the healthcare system and more
research should be executed focused on prevention including trials of CHG application
prior to intubation in noncardiac surgery patients. The APN can then use this knowledge
to train bedside nurses who provide oral care to ensure it is performed appropriately. As
research for VAP prevention advances, the diagnosis for this complex condition will be
more universally understood and more interventions put into practice to improve patient
outcomes.
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Appendix C-1
Descriptive Data Tables
Munro, C. L., Grap, M. J., Sessler, C. N., Elswick, R. K., Mangar, D., Karlnoski-Everall, R., & Cairns, P. (2015). Preintubation Application of Oral
Chlorhexidine Does Not Provide Additional Benefit in Prevention of Early-Onset Ventilator-Associated Pneumonia. Chest, 147(2), 328–334. doi:
10.1378/chest.14-0692
Purpose
Design
Site/Sample
Methods
Results
Limitations
Primary aim to test the effect
of preintubation 0.12% CHG
in reducing VAP risk.
Secondary aim to test the
effect of preintubation 0.12%
CHG on early ET
colonization.

Clinical
randomized
control trial

314 subjects from multiple clinical
areas (just prior to intubation,
including critical care units, EDs,
preoperative areas, procedural areas,
and medical surgical
units during rapid response or code
calls) were recruited by meeting
inclusion criteria and being just prior
to intubation at 2 large urban teaching
hospitals in Virginia. Intervention
group with CHG prior to intubation =
157, control group = 157.
IRB approved a waiver of prospective
consent but required written
documentation of consent (including
information about voluntary
withdrawal) from the subjects’
legally authorized representatives at
the earliest opportunity following
study enrollment.
Mean age (SD): intervention group =
59.5 (11.5), control group = 56.4
(16.5)
Gender: male/female in intervention
group = 55/45, control group= 60/40
Mean APACHE score (SD):
intervention group = 81.2 (25.2)
control group = 73.3
(26.3)
Exclusion criteria: Clinical diagnosis
of pneumonia at time of intubation.

Subjects randomly assigned to
intervention group who received
oral application of 5 mL CHG
0.12% solution before intubation
or to a control group who
received no CHG before
intubation.
All subjects received CHG twice
a day after intubation.
Preop: oral application of 5 mL
0.12% CHG solution by swab to
the oral cavity administered by
study personnel
Postop: 5 mL 0.12% CHG
administered by the responsible
nurse on a twice daily schedule
until extubation.
Subjects remained in the study
for a max of 6 days. If extubated
prior to 6 days, the
participation ended on the day of
extubation.
Groups were compared using a
repeated-measures model with
Clinical Pulmonary Infection
Score (CPIS) as the response
measure. ETTs were cultured at
extubation.
Clinical providers, laboratory
personnel, and radiologists were
all blinded to study groups.

Application of a preintubation
dose of CHG did not provide
benefit.
The P values from comparing
each group’s change from
baseline with study days 2, 3,
4, and 5 were 0.4217, 0.9930,
0.1484, and 0.1763,
respectively.
ETT colonization at
extubation was 20% in both
groups; no statistically
significant difference (P =
0.8656).
Mean CPIS remained below 6
(VAP threshold score) in both
groups.

Relatively small sample size
but priori power analysis
utilized to determine sample
size required.
May have been variations in
the procedure of swabbing the
oral cavities postintubation
since this was done by staff at
the hospital not the study
personnel.
Most subjects were extubated
prior to the full 5-day
intervention period.
No standard noted for the
procedure of swabbing to
ensure continuity.
Medical records were audited
to ensure postintubation
administration of CHG was
given so there may be a
chance it was scanned but not
given.
Does not state how
randomization was achieved
or what inclusion criteria was
besides being prior to
intubation without an existing
diagnosis of pneumonia.
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Appendix C-2
Houston, S., Hougland, P., Anderson, J. J., LaRocco, M., Kennedy, V., & Gentry, L. O. (2002). Effectiveness of 0.12% chlorhexidine gluconate oral rinse in
reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. American journal of critical care: an official publication, American
Association of Critical-Care Nurses, 11(6), 567–570.
Purpose
Design
Site/Sample
Methods
Results
Limitations
To test the effectiveness of
0.12% CHG oral rinse in
decreasing microbial
colonization of the respiratory
tract and nosocomial
pneumonia in patients
undergoing open heart
surgery.

Prospective,
randomized, casecontrolled clinical
trial

St. Luke’s Episcopal Hospital
in Houston, Tx; a tertiary care
center.
All eligible patients who
underwent aortocoronary
bypass graft and/or valve
surgery requiring
cardiopulmonary bypass were
invited to participate.
Exclusion criteria: death
during surgery, pregnant, or
had a preoperative respiratory
infection that had been
documented in the medical
record or reported by the
patient.
561 patients included in the
final data analysis, 270 were
randomized to the CHG
(experimental) group and 291
to the Listerine (control)
group.
Gender: male in intervention
group = 73%, control group =
79%

Randomized by medical record
numbers.
Intervention group was 0.12% CHG,
Listerine brand phenolic mouth rinse
was the standard agent for routine oral
care (control group).
Participants received 15 mL of either
CHG or Listerine oral rinse
preoperatively (30 sec swish & spit)
and twice daily postoperatively (30
sec swab) for 10 days postoperatively
or until extubation, tracheostomy,
death, or diagnosis of pneumonia.
Oral rinses dispensed by pharmacists
and administered by nurses.
Both groups received perioperative
prophylactic antibiotics per cardiac
surgery protocol.
Sputum samples were collected at the
time of extubation. For intubation >
24 hours of surgery, sputum samples
were obtained routinely every 48
hours until extubation.
Infections were diagnosed by using a
tool based on the CDC criteria for
nosocomial pneumonia

Rates of nosocomial
pneumonia were lower in
patients treated with CHG
than in patients treated with
Listerine, but the difference
was significant only in those
patients intubated >24 hours
who had the highest degree of
bacterial colonization.
The overall rate of
nosocomial pneumonia was
reduced by 52% (4/270 vs.
9/291; P =.21) in the CHGtreated patients.
Among patients intubated for
> 24 hours who had cultures
that showed microbial growth
(all pneumonias occurred in
this group); the pneumonia
rate was reduced by 58%
(4/19 vs. 9/18; P = .06) in
patients treated with CHG.
In patients at highest risk for
pneumonia (intubated >24
hours, with cultures showing
the most growth), the rate was
71% lower in the CHG group
than in the Listerine group
(2/10 vs. 7/10; P =.02).

Because of the low
overall pneumonia rate, a
large sample size would be
required to detect a
significant difference in
infection rate between the
CHG and the Listerine
groups.
There was no blinding in this
study.
Does not include age ranges
of participants.
Does not state how many
doses of oral rinse patients
received in total
preoperatively.
There could be error in selfreporting of the preoperative
doses that patients did at
home. Some doses may have
been skipped and not
reported.
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Appendix C-3
DeRiso, A. J., 2nd, Ladowski, J. S., Dillon, T. A., Justice, J. W., & Peterson, A. C. (1996). Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of
total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest, 109(6), 1556–1561.
https://doi.org/10.1378/chest.109.6.1556
Purpose
Design
Site/Sample
Methods
Results
Limitations
Primary aim was to test the
hypothesis that the
preoperative use of twicedaily 0.12% CHG oral rinse
can reduce nosocomial
infection rates in patients
undergoing open heart
surgery.
Additional outcome measures
• Overall nosocomial
infection rates
• Upper and lower
respiratory tract infection
rates
• Urinary tract infection rates
• Fungemias
• Line infection rates
• Wound infection rates
• Blood infection rates
• Other infections
• Nonprophylactic IV
antibiotic use
• Length of stay (LOS) in the
hospital
• Duration of intubation
• Need for reintubation
• In-hospital mortality

Prospective, randomized,
double-blind, placebocontrolled clinical trial

Cardiovascular ICU at
Lutheran Hospital of Indiana,
a tertiary care hospital
353 consecutive patients
undergoing coronary artery
bypass grafting, valve, or
other open-heart surgical
procedures chosen &
randomized.
Exclusion criteria:
intraoperative death,
preoperative infection or
intubation, pregnancy, heart
and lung transplant recipients,
and known hypersensitivity to
CHG.

Participants were randomized
by computer-driven random
number generator into either
the CHG 0.12% or placebo
solutions that were liquids of
comparable color, taste, and
smell were dispensed. Oral
rinse given preoperatively and
twice daily postoperatively
until discharge from the ICU
or death.
Doses were 0.5 fl oz (15 mL)
as an oropharyngeal rinse or
rigorously applied to the
buccal, pharyngeal, gingival,
tongue, and tooth surfaces for
30 seconds twice daily.

Consecutive eligible patients
over a 10-month period prior
to cardiac surgery were
invited to participate.

Both groups received
perioperative prophylactic
antibiotics per cardiac surgery
protocol.

Gender: male/female in
intervention group = 119/54,
control group = 123/57
Mean ages intervention group
= 64.1, control group = 63.5.

Patients who failed early
extubation (within 24 hours)
received tracheal aspirate
culture analysis at 48 hours
and then every 2 days until
discharged from the ICU or
death. Infections were
diagnosed by CDC criteria for
nosocomial pneumonia.

The overall nosocomial
infection rate was decreased
in the CHG-treated
patients compared to the
placebo group by 65% (8/173
vs. 24/180; p < 0.0l)
respectively.
Respiratory tract infections
were 69% less common in the
CHG-treated group compared
to the placebo group (5/
173 vs. 17/180; p < 0.05).
A reduction in mortality in
the CHG-treated group was
also noted (1.16% vs. 5.56%).

Does not specify how long
preoperatively patients used
CHG.
There could be error in selfreporting of the preoperative
doses that patients did at
home. Some doses may have
been skipped and not
reported.

49

Appendix C-4
Lin, Y. J., Xu, L., Huang, X. Z., Jiang, F., Li, S. L., Lin, F., Ye, Q. Y., Chen, M. L., & Lin, J. L. (2015). Reduced occurrence of ventilator-associated
pneumonia after cardiac surgery using preoperative 0.2% chlorhexidine oral rinse: results from a single-centre single-blinded randomized trial. The Journal of
hospital infection, 91(4), 362–366. https://doi.org/10.1016/j.jhin.2015.08.018
Purpose
Design
Site/Sample
Methods
Results
Limitations
To investigate the effect of
preoperative 0.2% CHG on
postoperative incidence of
VAP.

Single-center
single-blinded
randomized trial

Patients who met inclusion
and exclusion criteria from
those scheduled for cardiac
surgery between August
2013 and April 2014 at the
Fujian Medical University
Union Hospital, China.
The inclusion criteria were
conscious; age >18 years;
able to gargle in the
oropharynx by themselves;
and required orotracheal
intubation and mechanical
ventilation.
The exclusion criteria were
pneumonia before
intubation; history of
previous heart surgery and
intubation; or severe brain,
liver, or kidney disease.
Of the 94 patients who met
the inclusion criteria, 47
were randomized to the
CHG group and 47 to the
control group.

1:1 Randomization was by a
computer-generated random
number table and sealed
envelopes prepared by a
statistician. The treating
physician assigned the patient to
a group the day before surgery.
All patients were blinded to their
grouping.
In the CHG group, patients
gargled with 50 mL 0.2% CHG
30 minutes after all meals and 5
minutes after brushing teeth at
bedtime. CHG was gargled for
30 seconds and was repeated
three times at one-minute
intervals while the control group
gargled with normal saline
adhering to the same schedule.
All oral care and data collection
were done by same two trained
and blinded nurses to avoid bias.
The outcome of VAP was
diagnosed using the simplified
Clinical Pulmonary Infection
Score (CPIS) and was assessed
on days 1, 3, 5,
and 7 after intubation. A CPIS
score > 6 is suggestive of
pneumonia.

VAP occurred in 4 patients (8.5%) in
the CHG group and in 11 patients
(23.4%) in the control group (P=0.049).
VAP within 5 days was defined as early
onset and VAP after five days was late
onset.
In the CHG group, there was 1 case of
early onset VAP (25.0%) and 3 cases of
late onset VAP (75.0), whereas in the
control group, there were 9 cases of
early onset VAP (81.8%) and 2 cases of
late onset VAP (18.2%) (P = 0.027).
The relative risk for VAP in the CHG
group was 0.36 8.5% versus 23.4% in
the control group
The absolute risk reduction was 14.9%
in the CHG group and (23.4%/8.5%).
The number needed to treat was 6.7
(1/0.149).
CPIS scores were not different between
the two groups on postoperative day 1;
however, they were significantly lower
in the CHG group on the 3rd (P =
0.024) and 5th (P = 0.005) days when
compared to the controls.
Since only 2 and 3 cases completed
data collection on the 7th day in the
CHG and control groups, respectively,
because they were extubated no
analysis could be performed.

The preoperative rinse was used
the day before surgery after
meals and before bed; some
patients may have used different
amounts of doses based on how
many meals eaten that day.
Total mL of preoperative CHG
and saline was not disclosed.
Risk for self-reporting error by
patients about how often they
performed the preoperative rinse
The sample size was small and
to achieve a power of 80% at a
risk ratio of 0.36 over 90
patients would have been
required in each arm.
The presence of VAP was only
analyzed for the first seven
postoperative days.
Unclear study design stating 1:1
randomization by computer
generator but then states
physician assigned the groups.
Study does not make clear if the
two trained and blinded nurses
performing oral care, data
collection, and diagnosis of
VAP were from their team or
the hospitals.
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Appendix D-1
CASP Checklist
Munro, C. L., Grap, M. J., Sessler, C. N., Elswick, R. K., Mangar, D., Karlnoski-Everall, R., &
Cairns, P. (2015). Preintubation Application of Oral Chlorhexidine Does Not Provide Additional
Benefit in Prevention of Early-Onset Ventilator-Associated Pneumonia. Chest, 147(2), 328–334.
doi: 10.1378/chest.14-0692
1

Did the trial address a clearly focused issue?

Yes

Can’t No
tell

2

Was the assignment of patients to treatments randomized?

Yes

Can’t No
tell

3

Were all the patients who entered the trial properly accounted for at
its conclusion?

Yes

Can’t No
tell

4

Were patients, health workers and study personnel ‘blind’ to
treatment?

Yes

Can’t No
tell

5

Were the groups similar at the start of the trial?

Yes

Can’t No
tell

6

Aside from the experimental intervention, were the groups treated
equally?

Yes

Can’t No
tell

7

How large was the treatment effect? ETT colonization at extubation
was, 20% in both groups (no statistically significant difference P
=0.8656).

Yes

Can’t No
tell

8

How precise was the estimate of the treatment effect? A logistic
regression analysis was performed using the binary response
variable of colonization or no colonization and dependent variables
for group, length of intubation, and group-by-length-of-intubation
interaction. The probability of a type 1 error (alpha) was set to 0.05.

Yes

Can’t No
tell

9

Can the results be applied in your context? (or to the local
population?)

Yes

Can’t No
tell

10

Were all clinically important outcomes considered?

Yes

Can’t No
tell

11

Are the benefits worth the harms and costs?

Yes

Can’t No
tell
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Houston, S., Hougland, P., Anderson, J. J., LaRocco, M., Kennedy, V., & Gentry, L. O. (2002).
Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial
pneumonia in patients undergoing heart surgery. American journal of critical care: an official
publication, American Association of Critical-Care Nurses, 11(6), 567–570.
1

Did the trial address a clearly focused issue?

Yes

Can’t
tell

No

2

Was the assignment of patients to treatments randomized?

Yes

Can’t
tell

No

3

Were all the patients who entered the trial properly accounted for at
its conclusion?

Yes

Can’t No
tell

4

Were patients, health workers and study personnel ‘blind’ to
treatment?

Yes

Can’t
tell

No

5

Were the groups similar at the start of the trial?

Yes

Can’t
tell

No

6

Aside from the experimental intervention, were the groups treated
equally?

Yes

Can’t
tell

No

7

How large was the treatment effect? The overall rate of nosocomial
pneumonia was reduced by 52% (4/270 vs. 9/291; P=.21) in the
CHX patients.

Yes

Can’t
tell

No

8

How precise was the estimate of the treatment effect? This sample
size was sufficient to detect a 0.20 effect size with 99% power.

Yes

Can’t
tell

No

9

Can the results be applied in your context? (or to the local
population?)

Yes

Can’t
tell

No

10

Were all clinically important outcomes considered?

Yes

Can’t
tell

No

11

Are the benefits worth the harms and costs?

Yes

Can’t
tell

No
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DeRiso, A. J., 2nd, Ladowski, J. S., Dillon, T. A., Justice, J. W., & Peterson, A. C. (1996).
Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory
infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest,
109(6), 1556–1561. https://doi.org/0.1378/chest.109.6.1556
1

Did the trial address a clearly focused issue?

Yes

Can’t
tell

No

2

Was the assignment of patients to treatments randomized?

Yes

Can’t
tell

No

3

Were all the patients who entered the trial properly accounted for at
its conclusion?

Yes

Can’t No
tell

4

Were patients, health workers and study personnel ‘blind’ to
treatment?

Yes

Can’t
tell

No

5

Were the groups similar at the start of the trial?

Yes

Can’t
tell

No

6

Aside from the experimental intervention, were the groups treated
equally?

Yes

Can’t
tell

No

7

How large was the treatment effect? 69% reduction in the incidence Yes
of total respiratory tract infections in the CHX-treated group (17/180
vs. 5/173; p<0.05). A reduction in mortality in the CHX-treated
group was also noted (1.16% vs. 5.56%).

Can’t
tell

No

8

How precise was the estimate of the treatment effect? Statistical
analysis was carried out via computer using software (Systat
Statistical). Analysis of variance was used to compare numeric data,
while the x2 test with Yates' correction or the Fisher's Exact Test
was used for categorical data depending on the sample size. In all
cases, significance was defined as p<0.05.

Yes

Can’t
tell

No

9

Can the results be applied in your context? (or to the local
population?)

Yes

Can’t
tell

No

10

Were all clinically important outcomes considered?

Yes

Can’t
tell

No

11

Are the benefits worth the harms and costs?

Yes

Can’t
tell

No
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Lin, Y. J., Xu, L., Huang, X. Z., Jiang, F., Li, S. L., Lin, F., Ye, Q. Y., Chen, M. L., & Lin, J. L.
(2015). Reduced occurrence of ventilator-associated pneumonia after cardiac surgery using
preoperative 0.2% chlorhexidine oral rinse: results from a single-centre single-blinded randomized
trial. The Journal of hospital infection, 91(4), 362–366. https://doi.org/10.1016/j.jhin.2015.08.018

1

Did the trial address a clearly focused issue?

Yes

Can’t No
tell

2

Was the assignment of patients to treatments randomized?

Yes

Can’t No
tell

3

Were all the patients who entered the trial properly accounted for at
its conclusion?

Yes

Can’t No
tell

4

Were patients, health workers and study personnel ‘blind’ to
treatment?

Yes

Can’t No
tell

5

Were the groups similar at the start of the trial?

Yes

Can’t No
tell

6

Aside from the experimental intervention, were the groups treated
equally?

Yes

Can’t No
tell

7

How large was the treatment effect? VAP occurred in four patients
(8.5%) in the chlorhexidine group and in 11 patients (23.4%) in the
control group (P ¼ 0.049).

Yes

Can’t No
tell

8

How precise was the estimate of the treatment effect? Based on a
Yes
previous study, the estimated incidence of VAP was 30% in the
placebo group and 15% in the study group, resulting in an estimated
sample size of 98 patients in each arm, for a power of 80% and alpha
=0.05.

Can’t No
tell

9

Can the results be applied in your context? (or to the local
population?)

Yes

Can’t No
tell

10

Were all clinically important outcomes considered?

Yes

Can’t No
tell

11

Are the benefits worth the harms and costs?

Yes

Can’t No
tell
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Appendix E
Cross Study Analysis
Study/Year
Munro et al., 2015

Identified
Placebo
No preintubation
CHG

CHG Dose/
Frequency
Preintubation: 5 mL
0.12% CHG by swab
to the oral cavity
administered by study
personnel
Postop: 5 mL 0.12%
CHG administered by
the responsible nurse
twice daily until
extubation

Effect on Incidence of
VAP (Results)
Application of a
preintubation dose of
CHG did not provide
benefit in reducing
incidence of VAP
Mean CPIS < 6 (VAP
threshold score) in both
groups.
Secondary aim of
evaluating preintubations
impact on ETT
colonization: both groups
were < 20% colonized
with no significant
difference (P = 0.8656).

Houston et al., 2002

15 mL Listerine
brand phenolic
mouth rinse
(Given on same
schedule as CHG
administration)

15 mL 0.12%
preoperatively (30
second swish & spit)
and twice daily
postoperatively (30
second swab) for 10
days postoperatively
or until extubation,
tracheostomy, death,
or diagnosis of
pneumonia.

The overall rate of
nosocomial pneumonia
was reduced by 52%
(4/270 vs. 9/291; P = .21)
in the CHG-treated
patients.
Among patients intubated
for > 24 hours who had
cultures that showed
microbial growth (all
pneumonias occurred in
this group); the
pneumonia rate was
reduced by 58% (4/19 vs.
9/18; P = .06) in patients
treated with CHG.
In patients at highest risk
for pneumonia (intubated
>24 hours, with cultures
showing the most
growth), the rate was 71%
lower in the CHG group
than in the Listerine group
(2/10 vs. 7/10; P =.02).
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Identified
Placebo
Similar chemical
makeup without
CHG or
antimicrobial
properties.
Identical
packaging.
(Given on same
schedule as CHG
administration)

Lin et al., 2015

0.9% NS
(unspecified
amount)
(Given on same
schedule as CHG
administration)

CHG Dose/
Frequency

Effect on Incidence of
VAP (Results)

Twice daily
preoperative 0.12%
CHG (unspecified for
how many days
preoperatively). Then
postoperatively 15
mL 0.12% as an
oropharyngeal rinse
or rigorously applied
to the buccal,
pharyngeal, gingival,
tongue, and tooth
surfaces for 30
seconds twice daily
until discharge from
the ICU or death.

Respiratory tract
infections
were 69% less common in
the CHG-treated group
compared to the placebo
group (5/173 vs. 17/180;
p < 0.05).

50 mL 0.2% CHG 30
minutes after all
meals and 5 minutes
after brushing teeth at
bedtime. Either
solution was gargled
for 30 seconds and
was repeated three
times at one-minute
intervals. Once
intubated both groups
had oral rinse with 50
mL of 0.2% CHG
four times a day.

VAP occurred in 4
patients (8.5%) in the
CHG group and in 11
patients (23.4%) in the
control group (P = 0.049).
Absolute risk reduction
was 14.9% (23.4%/8.5%).

